Glaucoma

Othera Pharmaceuticals' topical beta blocker, OT-730, indicated for the reduction of intraocular pressure (IOP) in subjects with ocular hypertension and open-angle glaucoma, has begun a Phase I/II clinical trial for safety and efficacy.

SOLX 790, a glaucoma laser, has received 510(k) clearance from the FDA and can now be used for Titanium:Sapphire laser trabeculoplasty (TLT) in the United States, the laser's manufacturer, SOLX, has announced.

iScience Interventional has been granted 510k clearance from the FDA for its canaloplasty microcatheter for the catheterization and viscodilation of the Schlemm's canal in adult patients with primary open-angle glaucoma (POAG).

A study published in the September issue of the British Journal of Ophthalmology, has discovered that wearing swimming goggles may elevate intraocular pressure (IOP).

There is a large variation in the blood flow to the macula across a 24-hour period in old, but not young, eyes, according to results published in the August issue of the Journal of Glaucoma.

Ophthalmologists today are more likely to begin treatment to reduce intraocular pressure (IOP) at lower levels than twenty years ago, according to a study published in the Journal of Glaucoma, August 2008.

Understanding the glaucoma continuum enables earlier detection and better monitoring of the disease, according to Dr Theodore Krupin.

Pfizer has announced that it does not plan to begin a Phase III trial of its experimental compound PF-03187207 for glaucoma and ocular hypertension in Asia.

Augmenting combined phacoemulsification and deep sclerectomy (PDS) with intraoperative mitomycin C (MMC) is safe and likely to produce lower intraocular pressure (IOP) values than conducting PDS without MMC, according to the results of a study published in the August 2008 issue of Eye.

Many UK institutions are not compliant with current international guidelines on tonometer disinfection, according to a study published in the August 2008 issue of Eye.

Glaucoma patients are at an increased risk of developing ocular surface disease (OSD) in at least one eye, according to a study published in the August 2008 issue of the Journal of Glaucoma.

The protein/peptide patterns in the aqueous humour of primary open-angle glaucoma (POAG) subjects differs significantly from that of control subjects, according to a study published in the August 2008 issue of Molecular Vision.

Patients with glaucoma are not at an increased risk of developing systemic vascular disease, according to a study published in the August 2008 issue of the Acta Ophthalmologica.

Glaucoma treatment can, in certain metrics, improve quality of vision, according to a study published in the August 2008 issue of Eye.

Patients with thicker corneas are less likely to progress to primary open angle glaucoma (POAG) from ocular hypertension (OHT), according to a study published in the June 2008 issue of Contact Lens and Anterior Eye.

Genetic factors explain up to 74% of the variability in intraocular pressure (IOP) levels, according to a study published in the July 2008 issue of the British Journal of Ophthalmology.

A refinement in the manufacturing of contact lens material has enabled scientists to build a contact lens with an integrated sensor than can detect changes in intraocular pressure (IOP), according to results published in the July 2008 issue of Advanced Functional Materials.

Bottles of timolol ophthalmic solution 0.25% and 0.5% (Sandoz Canada Inc.) have been recalled in Canada because of an increased risk of adverse events.

The risk of adverse events following implantation of a glaucoma drainage device (GDD) is higher than the risk following either primary trabeculectomy (PT) or trabeculectomy with scarring (TS), according to results of a study published in the July 2008 issue of Ophthalmology.

The Glaucoma Foundation in the US has created an award scheme for innovation and excellence in glaucoma, recognizing the contribution of individuals who have "played a unique and significant role in promoting the medicine and science of glaucoma".

Performing LASIK in patients with glaucoma should be carefully considered before making the commitment because of changes in the eye that might result in lower IOP measurements, according to two ophthalmologists. PRK, however, might be a better option for this subgroup of patients, suggests one surgeon.

Timolol, latanoprost, and the fixed combinations of latanoprost/timolol (Xalcom; Pfizer) and dorzolamide/timolol (Cosopt; Merck) have equal efficacy and tolerability as well as equal levels of patient satisfaction, according to a study published online, ahead of print, by Graefe's Archive for Clinical and Experimental Ophthalmology.

INO-8875, an Adenosine 1 agonist in Phase I testing for the treatment of glaucoma, has begun patient enrolment.

A survey, released by the global campaign, All Eyes on Glaucoma, has revealed that more than 8.4 million people in Asia will be blinded by glaucoma by 2010 if they do not undergo treatment.

Should glaucoma drainage devices still be viewed as the last resort? asks Professor Walter Konen.

High caffeine intake is associated with an increased risk of high-tension primary open angle glaucoma (POAG) in subjects with a positive family history of glaucoma, according to a study published in the May 2008 issue of Investigative Ophthalmology & Visual Science.

Oxidative stress may play a role in the pathogenesis of primary open angle glaucoma (POAG), according to a study published in the June/July 2008 issue of the Journal of Glaucoma.

A new study shows that costs associated with glaucoma will more than double by 2025.

OT134, a laser therapy for the reduction of intraocular pressure, has completed the follow-up period of its first human clinical study.

The EyeRoute Image Management System, which provides a remote view of a Spectral Domain OCT system, has been introduced by Topcon Medical Systems.